Market Watch: Is Healthcare Becoming a Defensive Investment Destination?

By Sugandh Khandelwal

The October performance provides an interesting indication.While the broader market faced pressure, healthcare and pharmaceuticals continued to demonstrate comparatively stronger returns.TISHHA’s Chief Editor Sugandh Khandelwal analyses the pre and post Diwali performance of healthcare stocks, and explores the prospects for the hospital industry after Diwali.

Healthcare demand is relatively less discretionary than many other consumption categories. Patients cannot indefinitely postpone emergency surgeries, cancer treatment, cardiac procedures or critical care.This gives hospital companies a degree of revenue resilience. However, defensive demand does not mean that hospital stocks are immune to market corrections.

Hospital businesses remain exposed to high capital expenditure, expensive medical equipment, rising salaries, doctor acquisition costs, regulatory intervention and competition.The next phase of investment returns will therefore depend on financial execution rather than the healthcare growth story alone. The performance of India’s hospital and healthcare stocks before Diwali 2026 is an important indicator of how investors are viewing the next phase of growth in the Indian healthcare industry.

For this analysis, it is important to look beyond whether individual stocks moved up or down. The more meaningful questions are whether hospital stocks outperformed the broader market, whether investors continued to favour large hospital chains, how diagnostic and pharmaceutical companies performed in comparison and whether the market is rewarding actual earnings growth or merely future expansion expectations.

To understand the details, we need to examine the sector across two dimensions:

1. Hospital Giants: Apollo Hospitals, Max Healthcare, Fortis Healthcare, Narayana Hrudayalaya, Aster DM Healthcare, Global Health (Medanta), and Yatharth Hospital.
2. Broader Healthcare Sector: Diagnostics, pharmaceuticals, healthcare services and medical technology.

The central distinction is between a fundamentally growing healthcare industry and the stock-market valuation investors are willing to pay for that growth.

Healthcare remained in positive territory although it was not among the strongest-performing sectors. IT was the standout performer, while pharmaceutical companies also performed better than the hospital sector in several individual stock comparisons. So what does this mean for healthcare?Healthcare demonstrated relative resilience during a period when a substantial section of the broader market was struggling. However, this resilience was not equally distributed across all healthcare businesses.

Performance of India’s major hospital stocks before Diwali

A particularly useful snapshot comes from the healthcare sector trading update published on 30 October 2026, which provides one-month share-price movements for leading hospital companies.

One-month share-price return approximately through 30 October 2026

What does this table tell us?

Apollo Hospitals emerged as a relative outperformer. Apollo’s 3.2% gain was significant because most of the other large hospital chains were trading lower during the same period. This suggests that investors were relatively more comfortable with Apollo’s diversified healthcare business and earnings visibility. Apollo is not merely a hospital operator. Its business spans hospitals, pharmacies, diagnostics and digital healthcare. This diversification gives it multiple revenue streams and potentially reduces dependence on the performance of any single business vertical.Fortis demonstrated relative stability.Fortis registered a marginal 0.2% gain. Although this was not a particularly strong performance, it was better than the majority of hospital companies in the comparison. It has been strengthening its hospital network, improving operational efficiency and focusing on higher-value medical services. Its relatively stable share-price performance suggests that investors were not uniformly negative about the hospital sector.

Similarly Max Healthcare experienced a correction. Max declined 7.5% over the month. This is noteworthy because Max has been among the prominent growth stories in India’s private hospital industry.The correction should not automatically be interpreted as deterioration in its business fundamentals. Investors may have been reassessing the valuation premium attached to its expansion plans, future earnings and capacity additions.

Medanta and Narayana also faced pressure.Medanta lost 7% while Narayana Hrudayalaya declined 4.1%. Both companies have established positions in specialised and tertiary healthcare.The difference in their business models is important. Medanta has a strong presence in complex tertiary and quaternary care while Narayana has historically built its business around high-volume, cost-efficient speciality care.Their share-price weakness indicates that a strong clinical reputation or growing demand for specialised healthcare does not necessarily translate into immediate stock-market gains.

Yatharth and smaller hospital companies experienced sharper corrections.Yatharth declined 10.2%, while Shalby lost 13.1%. These movements suggest that smaller hospital chains may be more vulnerable to changes in investor risk appetite, liquidity and valuation expectations.This is particularly relevant for investors comparing established national hospital networks with emerging regional chains.

The hospital sector was not the only healthcare segment facing market pressure

The diagnostic and medical-device segment also showed mixed performance.One-month share-price performance through approximately 30 October 2026 was as follows:

This underlines an important distinction.The demand for diagnostic services in India continues to benefit from preventive healthcare, increasing disease awareness, a growing insured population and the expansion of organised diagnostic networks.Yet, diagnostic companies did not uniformly benefit from this underlying demand story in the stock market.Investors are increasingly looking at the economics of individual businesses: test volumes, realisations per patient, laboratory utilisation, network expansion costs and competitive pricing.

The big question is why did hospital stocks correct despite strong industry fundamentals?

This is arguably the most important part of the pre-Diwali analysis.There were several developments that influenced sentiment towards hospital companies.

A. Drug-pricing regulation and the Supreme Court issue

In October 2026, hospital stocks came under pressure following concerns about medicine mark-ups in private hospitals.The issue gained prominence after Supreme Court observations regarding the difference between procurement prices and prices charged to patients. Subsequently, the government announced a 30% trade-margin ceiling on non-scheduled anti-cancer medicines.The announcement generated different reactions across hospital companies. On 9 October, Apollo gained 4.72%, Fortis advanced 3.05%, and Manipal Health Enterprises gained 2.52%, while Healthcare Global Enterprises declined approximately 5.2%. Why does this matter?Oncology is an important revenue-generating speciality for several large hospital chains. Hospitals may earn revenue not only from consultations, procedures, surgeries and room charges but also from medicines and associated services.

A regulatory restriction on medicine mark-ups can therefore influence hospital economics.However, the impact should not be exaggerated. A diversified multispeciality hospital’s profitability depends on several revenue streams. The actual effect will vary according to its oncology contribution, procurement structure and medicine-related margins.The market is therefore trying to determine whether regulatory intervention will remain limited to specific medicines or become a broader pricing-control mechanism for private healthcare.

B. New hospital capacity is creating short-term margin pressure

The second major concern is expansion.India’s large hospital groups are investing heavily in additional beds, new hospitals, specialitycentres and geographical expansion.However, newly commissioned beds do not immediately generate optimal returns.A new hospital must first establish its medical team, attract patients, build referral networks, improve occupancy and stabilise operating costs.This creates a gap between capital expenditure and actual profitability.For instance, a hospital may add 300 beds but those beds may take several quarters to achieve commercially sustainable occupancy.During this period, depreciation, employee expenses, maintenance and other operating costs can affect EBITDA margins.This explains why investors are increasingly distinguishing between hospital companies that are expanding and companies that are successfully converting expansion into earnings.

C. Valuation concerns

Hospital companies have attracted considerable investor interest because of India’s long-term healthcare demand. However this has also resulted in high valuation expectations for several prominent hospital chains.When a stock is already trading at a premium valuation even good quarterly results may not be sufficient to push its price higher.Investors want results that exceed expectations.For example, a hospital company reporting 15% revenue growth may still witness a share-price correction if the market had anticipated 20% growth or if its operating margins have weakened.The market is not simply rewarding revenue growth anymore. It is demanding profitable growth.

What are the prospects for the hospital industry after Diwali?

Despite the corrections, the medium- to long-term outlook for India’s hospital industry remains constructive.There are five structural factors worth watching.

First, India’s hospital bed requirement. The country’s growing population, increasing incidence of non-communicable diseases and demand for advanced medical treatment create a long-term opportunity for organised hospital chains.Second, the growth of medical insurance. Expansion of private health insurance and government-sponsored healthcare programmes can increase access to organised hospitals. However, claim settlements, package rates and reimbursement delays will remain important considerations.Third, specialised healthcare. Oncology, cardiology, neurosciences, organ transplantation, nephrology and critical care are becoming increasingly important areas of hospital investment. These specialities can support higher-value treatment offerings, although they require substantial investment and skilled medical professionals.Fourth, Tier-2 and Tier-3 expansion. This could become one of the most significant growth opportunities. Established hospital groups are increasingly looking beyond metropolitan cities.

Cities such as Bareilly, Agra, Meerut, Gorakhpur and Kanpur can serve as regional healthcare destinations for surrounding districts. Their potential depends on local purchasing power, insurance penetration, doctor availability, competition, disease patterns and referral networks. Lastly, consolidation and institutional capital. Private equity investment, acquisitions and strategic partnerships are reshaping the competitive landscape. Established hospital groups have an opportunity to acquire regional networks, expand geographical coverage and improve operational efficiencies.

However, investors must distinguish between expansion announcements and actual financial returns from these investments.

 What should investors monitor in the next quarterly results?

The September quarter FY27 results were expected to be particularly important for the hospital sector.

A market preview published on 14 October highlighted healthy patient volumes, capacity additions and improving occupancy as the key earnings drivers. It also cautioned that margins could remain under pressure while new hospitals ramp up.

Here are the financial indicators that deserve attention:

One indicator deserves particular attention: ARPOB (Average Revenue Per Occupied Bed).A hospital may increase its bed capacity, but if its average revenue per occupied bed remains stagnant, the financial benefits of expansion may take longer to materialise.Similarly, a hospital with high occupancy but deteriorating EBITDA margins may be experiencing rising operating costs or an unfavourable treatment mix.

The pre-Diwali performance of healthcare stocks in 2026 offers an important lesson for the Indian hospital industry.The sector’s underlying fundamentals remain strong, but the stock market is no longer rewarding every hospital company equally.Apollo Hospitals demonstrated relative strength, Fortis remained comparatively stable while Max Healthcare, Medanta, Narayana and several emerging hospital chains experienced corrections.The pharmaceutical segment performed even better.

For the hospital industry, the next phase will be determined by three critical factors: the ability to expand capacity, the ability to improve occupancy and the ability to translate revenue growth into sustainable profitability.There is also a larger implication for hospital promoters and healthcare entrepreneurs.For regional hospital operators, this presents both an opportunity and a challenge. The increasing interest of institutional capital in India’s healthcare market could accelerate consolidation and create new competition in Tier-2 cities.The real story is not that healthcare stocks corrected before Diwali. The real story is that healthcare continued to outperform the broader market despite corrections in several of its leading hospital companies.That distinction is important when assessing the future of India’s hospital industry.

Subscribe TISHHA